ResearcherCollabResearcherCollab
Sign inJoin free →
Parham Panahi

Parham Panahi

Medicine
Independent Researcher · Iran
Connect →
3
Publications
0
Collaborations
0
Active calls

Research keywords

MedicalNeurosciencePharmacologyCardiologyPathologyHealth

Publications

3

A meta-analysis update evaluating the treatment effects of donepezil alone versus donepezil combined with memantine for Alzheimer's disease

IBRO Neuroscience Reports · 2025

Background: Alzheimer's disease (AD) remains a significant global health problem, with ongoing debates about the most effective treatment approach. While donepezil monotherapy has been traditionally used, recent interest has focused on combining it with memantine. This updated meta-analysis aimed to compare the efficacy of donepezil monotherapy versus its combination with memantine for treating AD. Method: A literature search was conducted in the PubMed, Scopus, and Google Scholar databases up to February 14, 2024. Randomized controlled trials (RCTs) comparing donepezil monotherapy with donepezil combined with memantine in AD patients were included. The quality of each selected study was assessed using the Joanna Briggs Institute (JBI) risk-of-bias tool. Data on cognitive function, measured using the Mini-Mental State Examination (MMSE) and the Severe Impairment Battery (SIB), were extracted and analyzed using a random-effects model. Results: A total of four RCTs, including 1930 patients, met the inclusion criteria. Analysis using a forest plot revealed no significant difference in MMSE scores between monotherapy and combination therapy (OR = 0.54, 95 % CI: 0.06-4.60, p > 0.05). However, SIB scores showed a significant improvement with combination therapy (OR = 7.00, 95 % CI: 1.13-43.24, p < 0.05). Both analyses exhibited high heterogeneity (I² = 72 % for MMSE; I² = 89 % for SIB). The funnel plots suggested minor publication bias for the MMSE outcomes, but some asymmetry was observed in the results for SIB. Conclusion: This meta-analysis suggests that combination therapy with donepezil and memantine significantly benefits patients with severe cognitive impairment, as assessed by the SIB, compared to donepezil monotherapy. However, no significant advantage was observed in MMSE scores. The high heterogeneity among studies highlights the need for cautious interpretation and calls for larger, well-designed randomized controlled trials to further elucidate the comparative efficacy of these two therapeutic approaches in Alzheimer's disease.

Deep learning models for predicting heart disease risk using the UCI database: methods, performance, and clinical context

American Journal of Cardiovascular Disease · 2025

The Impact of the COVID-19 Pandemic on Laboratory Test Volume and Abnormal Rates in Emergency and Outpatient Clinics: A Single-Center Study

Research Square · 2024

Other Medicine researchers

ST
Silvia Tedesco
Fondazione Policlinico Universitario Agostino Gemelli · Italy
Rene Mih Tah
Rene Mih Tah
France
Zarifa Jamalova
Zarifa Jamalova
Università di Padova · Italy
SA
Saad Asghar
Allama Iqbal Medical College Lahore · Pakistan
Guillem Esteve Boncompte
Guillem Esteve Boncompte
Universitat de Lleida · Spain
Atuhaire Arnold
Atuhaire Arnold
Kabale University School Of Medicine · Uganda
ResearcherCollab
Want to collaborate with Parham?
Connect with researchers worldwide. Free to join.
Join ResearcherCollab →